Product Overview

Crinone Vaginal Gel 1.125 g is a prescription‑grade medication formulated to supply endogenous progesterone directly to the uterine environment. Each single‑use applicator delivers a calibrated 1.125 gram dose of micronized progesterone suspended in a clear, water‑based gel. The product is supplied in sealed, single‑dose units that include a sterile applicator, ensuring accurate dosing and minimizing contamination risk. Crinone is indicated for women undergoing assisted reproductive technology (ART) cycles, particularly embryo transfer, where luteal phase support with progesterone is essential. Manufactured by Merck Specialities Pvt Ltd, the gel is packaged in cartons containing 12, 6, or 3 individual gels, allowing flexibility for short‑term or extended treatment regimens. The formulation is free of preservatives and is designed for easy vaginal insertion, offering a convenient alternative to oral or intramuscular progesterone routes.

What is Crinone Vaginal Gel

Crinone belongs to the class of progesterone analogues used in reproductive endocrinology. Progesterone plays a pivotal role in preparing the endometrium for implantation and maintaining early pregnancy. In the context of female infertility, insufficient endogenous progesterone can compromise implantation success, especially after in‑vitro fertilization or intrauterine insemination. Crinone provides a physiologic dose of progesterone that mimics the natural luteal phase hormone, supporting the secretory transformation of the endometrium. The gel’s nanometer‑sized particles enhance surface area, facilitating rapid absorption across the vaginal mucosa. This delivery method bypasses first‑pass metabolism, resulting in more consistent systemic exposure compared with oral tablets.

Uses and Benefits

The primary clinical use of Crinone Vaginal Gel is luteal phase support in ART cycles, but it may also be prescribed for other conditions where progesterone supplementation is required, such as hormone replacement therapy for menopausal symptoms or for managing certain cases of endometrial hyperplasia. By delivering progesterone directly to the target tissue, Crinone helps reduce the risk of ovarian hyperstimulation and improves endometrial receptivity. Patients often report fewer gastrointestinal side effects compared with oral progesterone, and the once‑daily dosing simplifies adherence. Moreover, the gel’s sterile applicator eliminates the need for manual measurement, decreasing dosing errors. From a pharmacy perspective, Crinone is classified under female infertility treatments and is listed in major drug databases, confirming its legitimacy and regulatory approval.

How It Works

The mechanism of action of Crinone mirrors that of endogenous progesterone. Once administered, the gel dissolves in the vaginal fluid, releasing micronized progesterone that diffuses across the mucosal epithelium into surrounding stromal cells. Inside these cells, progesterone binds to intracellular receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This leads to increased production of insulin‑like growth factor‑1 (IGF‑1) and other growth factors that promote endometrial secretions and vascular development. The enhanced endometrial environment creates a more receptive niche for embryo implantation. Clinical studies cited by the NIH demonstrate that progesterone supplementation, including Crinone, can raise ongoing pregnancy rates by up to 10 % in assisted reproduction settings. For detailed scientific review, refer to the NIH’s database on reproductive hormones (https://www.nih.gov).

Dosage Guidelines

Dosage of Crinone must be individualized by a qualified healthcare professional based on the specific ART protocol. The standard regimen involves one single‑dose applicator (1.125 g) administered once daily, preferably in the evening, for a minimum of six days following embryo transfer. In some protocols, treatment may be extended to ten days if the embryo transfer occurs later in the cycle. Patients should be instructed to wash their hands before handling the applicator, to remove the protective cap, and to insert the entire contents of the gel into the vaginal canal using the provided applicator tip. The gel should not be expelled; if leakage occurs, the dose should be repeated under medical supervision. It is crucial to adhere strictly to the prescribed schedule, as inconsistent dosing can compromise endometrial readiness and reduce implantation odds. Always consult your fertility specialist before altering the dosing regimen.

Side Effects

Like all medications, Crinone may cause adverse effects, although most are mild and transient. The most frequently reported side effects include mild vaginal irritation, spotting, or a watery discharge immediately after application. Some users experience abdominal cramping, breast tenderness, or headache, which typically resolve without intervention. Rarely, more pronounced reactions such as severe pelvic pain, allergic dermatitis, or signs of ovarian hyperstimulation syndrome (OHSS) may occur; in such cases, immediate medical evaluation is recommended. Patients should be advised to report any unexpected bleeding, fever, or persistent discomfort to their clinician. The FDA’s drug safety database provides comprehensive information on reported events (https://www.fda.gov). Monitoring for adverse reactions is especially important during the first few cycles of treatment.

Warnings and Precautions

Crinone is contraindicated in individuals with known hypersensitivity to progesterone or any component of the formulation. It should not be used in patients with active liver disease, unexplained vaginal bleeding, or suspected pregnancy outside of a controlled ART setting. Caution is advised when co‑administering Crinone with other hormonal therapies, as combined effects may alter endometrial patterns unpredictably. Women who are breastfeeding should discuss potential risks with their physician, as progesterone can be excreted in milk. The medication must be stored at room temperature, protected from moisture and direct sunlight, and kept out of reach of children. If a dose is missed, the patient should not double up; instead, they should contact their healthcare provider for guidance. For official prescribing information, see the product label or the MedlinePlus resource (https://medlineplus.gov).

Frequently Asked Questions

Question 1: What is Crinone Vaginal Gel used for?
Answer: Crinone is prescribed to provide luteal phase support in assisted reproductive technology cycles, helping to prepare the uterine lining for embryo implantation.

Question 2: How should Crinone be stored?
Answer: Keep the sealed gel at room temperature, away from moisture and direct sunlight, and store it out of reach of children until use.

Question 3: Can Crinone be used together with other fertility medications?
Answer: Yes, Crinone is often combined with ovarian stimulants or embryo transfer protocols, but the exact combination should be directed by a fertility specialist.

Question 4: What should I do if I miss a dose?
Answer: If a dose is missed, do not double the next dose; instead, contact your healthcare provider for instructions on how to proceed safely.

Question 5: Is long‑term use of Crinone safe?
Answer: Crinone is intended for short‑term luteal support; prolonged use without medical supervision is not recommended, and any extended therapy should be evaluated by a physician.

Related Products

• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)
• ZyhCG 2000 (HCG 2000iu)
• Sifasi Aqua 5000 (HCG (Human Chorionic Gonadotropin))
• Clomiphene 50 mg (Generic)
• Clomiphene 100 mg (Generic)
• Clomiphene 25 mg (Generic)
• Progesterone Vaginal Gel 1.125 g (Generic)
• Fertomid 25 mg (Clomiphene)
• Clofert 50 mg (Clomiphene)
• Clofert 25 mg (Clomiphene)
• Clofert (Clomiphene)